Activity in US psoriatic arthritis sector

16 August 2017
2019_biotech_test_vial_discovery_big

In the most recent quarterly update of RealTime Dynamix Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use of Novartis’ (NOVN: VX) Cosentyx (secukinumab) to treat their patients with psoriatic arthritis (PsA).

Nonetheless, according to the report from market intelligence agency Spherix, this increasing user base has not translated into overall increases in biologic share.  Furthermore, in second-quarter 2016, rheumatologists anticipated doubling their Cosentyx share over the subsequent six month period, a projection that panned out and was fully realized in practice. However, since the end of 2016, rheumatologists have continued to forecast positive Cosentyx growth, but have failed to see those projections through.

The majority of rheumatologists indicate that "ideal" Cosentyx patients have previously failed at least one TNF agent, a group representing nearly half of all biologic-treated PsA patients, so what is at the source of Cosentyx' apparent plateau?  Just under one-third of rheumatologists report high satisfaction with the interleukin (IL)-17 inhibitor, a lower percent compared to the leading TNF agents and Johnson & Johnson's (NYSE: JNJ) Stelara (ustekinumab).  Furthermore, despite Cosentyx' association with strong efficacy in skin clearance, more rheumatologists prefer AbbVie's (NYSE: ABBV) Humira (adalimumab) over Cosentyx for patients with severe psoriasis.  Finally, use of Cosentyx continues to be hampered by rheumatologists' perceptions of inferior market access compared to more established biologic brands.

Pressure ahead from PsA agents in pipeline

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology